Boston Scientific (NYSE:BSX) Given "Outperform" Rating at Royal Bank Of Canada

Key Points

• Royal Bank Of Canada has restated its "outperform" rating for Boston Scientific with a price target of $125.00, suggesting a potential upside of 28.41% from the current stock price.
• Boston Scientific's latest earnings report showed an EPS of $0.75, exceeding expectations and representing a 22.8% year-over-year revenue growth.
• Insider trading activity included EVP Arthur C. Butcher selling 17,313 shares at an average price of $104.63, indicating significant movement in insider ownership.

Boston Scientific (NYSE:BSX - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Royal Bank Of Canada in a report issued on Monday,Benzinga reports. They currently have a $125.00 price objective on the medical equipment provider's stock. Royal Bank Of Canada's price target would indicate a potential upside of 28.41% from the stock's current price.

Other equities analysts also recently issued reports about the stock. Leerink Partners began coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Finally, BTIG Research reiterated a "buy" rating and issued a $127.00 target price on shares of Boston Scientific in a research note on Tuesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $118.38.

Boston Scientific Price Performance

BSX stock opened at $97.34 on Monday. The stock has a 50-day moving average price of $103.79 and a two-hundred day moving average price of $102.16. The stock has a market cap of $144.24 billion, a PE ratio of 58.01, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 EPS. The company's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last three months. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at $26,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the first quarter worth about $27,000. Finally, Kilter Group LLC bought a new stake in shares of Boston Scientific during the second quarter worth about $30,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.